Therapeutic Class
thumbnail
Deal MakingSanofi inks $1.2bn Novavax deal to bolster post-pandemic vax salesSanofi inks $1.2bn Novavax deal to bolster post-pandemic vax sales
Sanofi has signed a licensing deal worth up to $1.2 billion with Novavax to commercialize the latter’s adjuvanted COVID-19 vaccine and use the technology to create its own flu shot.